Top Markets
Coin of the day
Metagenomi, Inc. Common Stock Metagenomi, Inc. Common Stock

Metagenomi, Inc. Common Stock

MGX
Clasificación en acciones #25865
Metagenomi, Inc. operates as a biotechnology company focused on gene editing,... Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Precio por acción
$1.21
Última sincronización: 2026-08-20
Capitalización bursátil
$45.55M
Cambio (1 día)
-2.43%
Cambio (1 año)
-34.60%
País
US
Comercio Metagenomi, Inc. Common Stock (MGX)

Categoría

EPS de Metagenomi, Inc. Common Stock (MGX)
EPS a fecha de 2026 TTM: 0
Según los últimos informes financieros y el precio de las acciones de Metagenomi, Inc. Common Stock, el EPS actual de la empresa (TTM) es 0. Al final del año 2026, la empresa tenía un EPS de 0 igual a al EPS de 2026, que fue de 0.
Historial de EPS de Metagenomi, Inc. Common Stock desde 2026 hasta 2026
EPS al final de cada año
Año EPS Cambiar
Not enough data for the provided dates.
EPS de empresas similares o competidoras
Empresa EPS Diferencia de EPS País
$17.32 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH
$-7.98 -
US